Targeting β3-adrenergic receptors in the heart: Selective agonism and β-blockade

Journal of Cardiovascular Pharmacology

Volumn 69, Issue 2, 2017, Pages 71-78

  Cannavo, Alessandro ^a   Koch, Walter J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

G proteins; Heart failure; adrenergic receptor; blockers

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CATECHOLAMINE; METOPROLOL; MIRABEGRON; NEBIVOLOL;

ARTICLE; CARDIAC MUSCLE; CARDIOVASCULAR DISEASE; DRUG RECEPTOR BINDING; FATTY ACID OXIDATION; HEART; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; LIPOLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; VASCULAR ENDOTHELIUM; ANIMAL; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM; PROCEDURES;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADRENERGIC BETA-3 RECEPTOR ANTAGONISTS; ANIMALS; DRUG DELIVERY SYSTEMS; HEART; HEART DISEASES; HUMANS; RECEPTORS, ADRENERGIC, BETA-3;

EID: 85013772509     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000444     Document Type: Article

References (65)

1. Lin HH. G-protein-coupled receptors and their (bio) chemical significance win 2012 Nobel Prize in Chemistry. Biomed J. 2013;36:118-124.
2. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001;33:887-905.
3. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993;22(4 suppl A):61A-71A.
4. Cannavo A, Liccardo D, Koch WJ. Targeting cardiac b-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front Physiol. 2013;4:264.
5. Frielle T, Collins S, Daniel KW, et al. Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci U S A. 1987;84: 7920-7924.
6. Kobilka BK, Dixon RA, Frielle T, et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A. 1987;84:46-50.
7. Emorine LJ, Marullo S, Briend-Sutren MM, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989;245: 1118-1121.
8. Simard PM, Atgie C, Mauriege P, et al. Comparison of the lipolytic effects of norepinephrine and BRL 37344 in rat brown and white adipocytes. Obes Res. 1994;2:424-431.
9. Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol. 2010;59:135-163.
10. Skeberdis VA. Structure and function of beta3-adrenergic receptors. Medicina (Kaunas). 2004;40:407-413.
11. Moffett S, Mouillac B, Bonin H, et al. Altered phosphorylation and desensitization patterns of a human b2-adrenergic receptor lacking the palmitoylated Cys341. EMBO J. 1993;12:349-356.
12. Hutchinson DS, Chernogubova E, Dallner OS, et al. Beta-adrenoceptors, but not alpha-adrenoceptors, stimulate AMP-activated protein kinase in brown adipocytes independently of uncoupling protein-1. Diabetologia. 2005;48:2386-2395.
13. Dessy C, Moniotte S, Ghisdal P, et al. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation. 2004; 110:948-954.
14. Gauthier C, Langin D, Balligand JL. Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci. 2000;21:426-431.
15. Imbrogno S, Gattuso A, Mazza R, et al. b3-AR and the vertebrate heart: a comparative view. Acta Physiol (Oxf). 2015;214:158-175.
16. Evans BA, Papaioannou M, Hamilton S, et al. Alternative splicing generates two isoforms of the b3-adrenoceptor which are differentially expressed in mouse tissues. Br J Pharmacol. 1999;127:1525-1531.
17. Hutchinson DS, Bengtsson T, Evans BA, et al. Mouse beta 3a-and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways. Br J Pharmacol. 2002; 135:1903-1914.
18. Sato M, Hutchinson DS, Bengtsson T, et al. Functional domains of the mouse beta3-adrenoceptor associated with differential G protein coupling. J Pharmacol Exp Ther. 2005;315:1354-1361.
19. Gerhardt CC, Gros J, Strosberg AD, et al. Stimulation of the extracellular signal-regulated kinase 1/2 pathway by human beta-3 adrenergic receptor: new pharmacological profile and mechanism of activation. Mol Pharmacol. 1999;55:255-262.
20. Soeder KJ, Snedden SK, Cao W, et al. The beta3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism. J Biol Chem. 1999;274:12017-12022.
21. Gauthier C, Leblais V, Kobzik L, et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest. 1998;102: 1377-1384.
22. Gauthier C, Tavernier G, Charpentier F, et al. Functional beta3-adrenoceptor in the human heart. J Clin Invest. 1996;98:556-562.
23. Bristow MR, Hershberger RE, Port JD, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990;82(2 suppl):I12-I25.
24. Brixius K, Bloch W, Pott C, et al. Mechanisms of b3-adrenoceptorinduced eNOS activation in right atrial and left ventricular human myocardium. Br J Pharmacol. 2004;143:1014-1022.
25. Trappanese DM, Liu Y, McCormick RC, et al. Chronic b1-adrenergic blockade enhances myocardial b3-adrenergic coupling with nitric oxidecGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective b1-blocker therapy. Basic Res Cardiol. 2015;110:456.
26. Balligand JL. Cardiac salvage by tweaking with beta-3-adrenergic receptors. Cardiovasc Res. 2016;111:128-133.
27. Angelone T, Filice E, Quintieri AM, et al. Beta3-adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway. Acta Physiol (Oxf). 2008;193:229-239.
28. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122:216-238.
29. Takimoto E. Cyclic GMP-dependent signaling in cardiac myocytes. Circ J. 2012;76:1819-1825.
30. Abdallah Y, Gkatzoflia A, Pieper H, et al. Mechanism of cGMPmediated protection in a cellular model of myocardial reperfusion injury. Cardiovasc Res. 2005;66:123-131.
31. Abdallah Y, Gkatzoflia A, Gligorievski D, et al. Insulin protects cardiomyocytes against reoxygenation-induced hypercontracture by a survival pathway targeting SR Ca2+ storage. Cardiovasc Res. 2006;70:346-353.
32. Inserte J, Garcia-Dorado D. The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism. Br J Pharmacol. 2015; 172:1996-2009.
33. Kimura K, Sasaki N, Asano A, et al. Mutated human beta3-adrenergic receptor (Trp64Arg) lowers the response to beta3-adrenergic agonists in transfected 3T3-L1 preadipocytes. Horm Metab Res. 2000;32:91-96.
34. Csernus K, Pauler G, Erhardt É, et al. Effects of energy expenditure gene polymorphisms on obesity-related traits in obese children. Obes Res Clin Pract. 2015;9:133-140.
35. Mirrakhimov AE, Kerimkulova AS, Lunegova OS, et al. An association between TRP64ARG polymorphism of the B3 adrenoreceptor gene and some metabolic disturbances. Cardiovasc Diabetol. 2011;10:89.
36. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
37. Fischer V, Gabauer I, Tillinger A, et al. Heart adrenoceptor gene expression and binding sites in the human failing heart. Ann N Y Acad Sci. 2008;1148:400-408.
38. Moniotte S, Kobzik L, Feron O, et al. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. 2001;103:1649-1655.
39. Moniotte S, Balligand JL. Potential use of beta(3)-adrenoceptor antagonists in heart failure therapy. Cardiovasc Drug Rev. 2002;20:19-26.
40. Masutani S, Cheng HJ, Morimoto A, et al. b3-Adrenergic receptor antagonist improves exercise performance in pacing-induced heart failure. Am J Physiol Heart Circ Physiol. 2013;305:H923-H930.
41. Bundgaard H, Liu CC, Garcia A, et al. b(3) adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification. Circulation. 2010;122:2699-2708.
42. Galougahi KK, Liu CC, Bundgaard H, et al. b-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling. Trends Cardiovasc Med. 2012;22:83-87.
43. Mongillo M, Tocchetti CG, Terrin A, et al. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res. 2006;98:226-234.
44. Belge C, Hammond J, Dubois-Deruy E, et al. Enhanced expression of b3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation. 2014;129:451-462.
45. Niu X, Watts VL, Cingolani OH, et al. Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol. 2012;59:1979-1987.
46. García-Prieto J, García-Ruiz JM, Sanz-Rosa D, et al. b3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes. Basic Res Cardiol. 2014;109:422.
47. Rengo G, Parisi V, Femminella GD, et al. Molecular aspects of the cardioprotective effect of exercise in the elderly. Aging Clin Exp Res. 2013;25:487-497.
48. Calvert JW, ConditME, Aragón JP, et al. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of b(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res. 2011;108:1448-1458.
49. Salazar NC, Vallejos X, Siryk A, et al. GRK2 blockade with bARKct is essential for cardiac b2-adrenergic receptor signaling towards increased contractility. Cell Commun Signal. 2013;11:64.
50. Cannavo A, Liccardo D, Lymperopoulos A, et al. b adrenergic receptor kinase C-terminal peptide gene-therapy improves b2-adrenergic receptordependent neoangiogenesis after hindlimb ischemia. J Pharmacol Exp Ther. 2016;356:503-513.
51. Walther S, Pluteanu F, Renz S, et al. Urocortin 2 stimulates nitric oxide production in ventricular myocytes via Akt-and PKA-mediated phosphorylation of eNOS at serine 1177. Am J Physiol Heart Circ Physiol. 2014;307:H689-H700.
52. Zhang Z, Ding L, Jin Z, et al. Nebivolol protects against myocardial infarction injury via stimulation of beta 3-adrenergic receptors and nitric oxide signaling. PLoS One. 2014;9:e98179.
53. Sharma V, Parsons H, Allard MF, et al. Metoprolol increases the expression of beta(3)-adrenoceptors in the diabetic heart: effects on nitric oxide signaling and forkhead transcription factor-3. Eur J Pharmacol. 2008; 595:44-51.
54. Zhao Q, Wu TG, Jiang ZF, et al. Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure. Cardiovasc Drugs Ther. 2007;21:85-90.
55. Aragón JP, Condit ME, Bhushan S, et al. Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. J Am Coll Cardiol. 2011;58:2683-2691.
56. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198-1205.
57. Sorrentino SA, Doerries C, Manes C, et al. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional b1-blockade. J Am Coll Cardiol. 2011;57: 601-611.
58. Rengo G, Cannavo A, Liccardo D, et al. Vascular endothelial growth factor blockade prevents the beneficial effects of b-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure. Circ Heart Fail. 2013;6:1259-1267.
59. Suárez J, Rivera P, Arrabal S, et al. Oleoylethanolamide enhances b-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech. 2014; 7:129-141.
60. Schulze PC, Drosatos K, Goldberg IJ. Lipid use and misuse by the heart. Circ Res. 2016;118:1736-1751.
61. Abdurrachim D, Luiken JJ, Nicolay K, et al. Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models. Cardiovasc Res. 2015;106:194-205.
62. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578-588.
63. Bordicchia M, Pocognoli A, D'Anzeo M, et al. Nebivolol induces, via b3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes. J Hypertens. 2014;32:389-396.
64. Kashyap M, Tyagi P. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013;9:617-627.
65. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153:1589-1601.